Covalent targeting leads to the development of LIMK1 isoform-selective inhibitors
Sebastian Mandel(Goethe University Frankfurt), Stefan Knapp(Goethe University Frankfurt)
Cited by 0
Related Papers
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
|Cell|2012|1.7k
Bromodomains as therapeutic targets
|Expert Reviews in Molecular Medicine|2011|436
A designed ankyrin-repeat protein that targets Parkinson’s disease-associated LRRK2
|Journal of Biological Chemistry|2024|3
Repurposing of the RIPK1 selective benzo[1,4]oxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitor
|bioRxiv (Cold Spring Harbor Laboratory)|2025|2
Development of LRRK2 designed ankyrin-repeat proteins
|bioRxiv (Cold Spring Harbor Laboratory)|2023|1